Dizal Pharmaceutical
Dizal is a Shanghai biotechnology company built on small-molecule kinase inhibitors: sunvozertinib for EGFR exon 20 insertion lung cancer and DZD8586, a dual LYN and BTK inhibitor in the phase 3 TAI-SHAN6 trial for relapsed chronic lymphocytic leukaemia.
Overview
Dizal Pharmaceutical, based in Shanghai and listed in Shanghai, designs small-molecule drugs for cancer and immune disease. Its oncology pipeline centres on sunvozertinib, an EGFR inhibitor designed for exon 20 insertion mutations in non-small-cell lung cancer, and DZD8586, an oral inhibitor of LYN and BTK that crosses the blood-brain barrier and is being compared with investigator's choice therapy in relapsed or refractory chronic lymphocytic leukaemia. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +6
- phase 3 +3
- targets +2
- modalities +2
- regions +2
- registry trials +9
An oral drug for EGFR exon 20 insertion lung cancer that succeeded where mobocertinib failed; approved in China (2023) and the US (2025).
DZD8586 is an experimental small-molecule drug from Dizal Pharmaceuticals in phase 3 trials for chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.
Similar pages
not linked directly; found by shared links- CompanyCuris
Shares Chronic lymphocytic leukaemia and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCatalYm
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.